InsidersTradesSigma
Follow the Allovir, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Allovir, Inc. has logged 215 insider filings. The latest transaction was disclosed on 24 February 2025 (Cession). Among the most active insiders: Hagen Brett R. The full history is openly available.
215
Insider Decl.
n/a
Thresholds
€10m
3 ops.
Buy Volume
€16m
167 ops.
Sell Volume
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 February 2025
Declarations215 total
96 shares@ US$10.07580.6% of flowCommon StockSEC:0000950170-25-025633:0
106 shares@ US$10.07582.1% of flowCommon StockSEC:0000950170-25-025630:0
303 shares@ US$10.07580.0% of flowCommon StockSEC:0000950170-25-025634:0
116 shares@ US$9.45380.0% of flowCommon StockSEC:0000950170-25-009197:0
47 shares@ US$9.45380.9% of flowCommon StockSEC:0000950170-25-009205:0
32 shares@ US$9.45380.2% of flowCommon StockSEC:0000950170-25-009204:0
409 shares@ US$0.44010.4% of flowCommon StockSEC:0000950170-25-004834:0
332 shares@ US$0.44010.1% of flowCommon StockSEC:0000950170-25-004833:0
979 shares@ US$0.44010.0% of flowCommon StockSEC:0000950170-25-004832:0
57,549 shares0Common StockSEC:0000950170-24-135443:0
3,186 shares@ US$0.54850.0% of flowCommon StockSEC:0000950170-24-129259:0
8,706 shares@ US$0.54850.7% of flowCommon StockSEC:0000950170-24-129257:0
432 shares@ US$0.54850.5% of flowCommon StockSEC:0000950170-24-129258:0
554 shares@ US$0.54850.2% of flowCommon StockSEC:0000950170-24-129263:0
2,272 shares@ US$0.86493.7% of flowCommon StockSEC:0000950170-24-122335:0
10,609 shares@ US$0.86491.4% of flowCommon StockSEC:0000950170-24-122336:0
1,655 shares@ US$0.86490.8% of flowCommon StockSEC:0000950170-24-122334:0
5,136 shares@ US$0.86490.0% of flowCommon StockSEC:0000950170-24-122333:0
9,752 shares@ US$0.7791.1% of flowCommon StockSEC:0000950170-24-116645:0
479 shares@ US$0.7790.2% of flowCommon StockSEC:0000950170-24-116646:0
635 shares@ US$0.7790.9% of flowCommon StockSEC:0000950170-24-116644:0
1,546 shares@ US$0.7790.0% of flowCommon StockSEC:0000950170-24-116648:0
377 shares@ US$0.81480.6% of flowCommon StockSEC:0000950170-24-112913:0
1,493 shares@ US$0.81480.2% of flowCommon StockSEC:0000950170-24-112912:0
940 shares@ US$0.81480.0% of flowCommon StockSEC:0000950170-24-112914:0
25 of 215 declarations
关于 Allovir, Inc.
AlloVir, Inc. (ALVR) 是一家总部位于美国的生物制药公司，已在美国纳斯达克市场上市。该公司成立于2013年8月，其核心业务是异体、现成的病毒特异性T细胞（VST）平台，旨在恢复重症病毒疾病患者的免疫力，特别是移植受者等免疫功能低下患者。公司总部位于马萨诸塞州列克星敦。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312525019332/d888593ds4a.htm?utm_source=openai)) 在其大部分历史中，AlloVir 的产品线集中于 posoleucel (ALVR105)，这是一种多病毒VST疗法，旨在靶向腺病毒、BK病毒、巨细胞病毒、Epstein-Barr病毒、HHV-6和JC病毒。该公司还开发了用于呼吸道病毒疾病的 ALVR106，以及其他VST候选药物。从战略上讲，这使得 AlloVir 成为利基免疫治疗领域的高度专业化参与者，其平台方法、现成部署的潜力以及对治疗选择有限的严重病毒并发症的关注使其与众不同。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000095017025035143/alvr-20241231.htm?utm_source=openai)) 从竞争角度来看，AlloVir 的主要优势在于其在工程T细胞疗法方面的深厚科学实力以及对未满足需求高的适应症的关注。与此同时，投资案例始终伴随着巨大的临床和融资风险。该公司没有获批产品，也没有商业产品收入，其备案文件显示多年来一直处于显著亏损状态。更重要的是，AlloVir 的近期概况因与 Kalaris Therapeutics 的合并协议而重塑，该协议已于2025年3月获得 AlloVir 股东批准。合并后的公司预计将更名为 Kalaris Therapeutics, Inc.，并在纳斯达克资本市场以股票代码 KLRS 交易。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312526177387/d69530dars.pdf)) 近期公司发展表明了重大的战略转型。2025年年度报告指出，AlloVir 没有获批产品，也没有产生产品收入，同时还提到与合并相关的现金和2025年的私募配售增强了资产负债表。报告进一步指出，TH103 现已成为合并后公司早期开发阶段的领先候选产品。对于法语投资者而言，ALVR 因此最好被理解为一家具有真正平台创新的临床阶段生物技术公司，但也存在大量现金消耗的历史、对外部融资的依赖以及公司发展轨迹已偏离其最初的纯VST故事。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1754068/000119312526177387/d69530dars.pdf))
